Background. Myocardial ischemia followed by reperfusion results in endothelial dysfunction character-
R ecent investigations have characterized endothelium-derived relaxing factor (EDRF) as nitric oxide (NO) or a labile nitroso compound that spontaneously liberates NO.1-4 In the vascular system, NO release from endothelial cells accounts for vasorelaxation in vessels5 as well as inhibition of platelet4'6 and neutrophil7 aggregation. NO is produced from the semiessential amino acid L-arginine as it is converted to L-citrulline by NO we hypothesized that the administration of exogenous L-arginine would maintain NO levels and thereby attenuate endothelial dysfunction and myocardial necrosis after ischemia/reperfusion. Accordingly, the objectives of this study were to evaluate the cardioprotective effects of exogenous L-arginine administration in myocardial ischemia/reperfusion, and determine the mechanisms of any observed cardioprotective effects of L-arginine, particularly as they relate to endothelial function.
Methods
Adult male cats were anesthetized with sodium pentobarbital (30 mg/kg i.v.). An intratracheal cannula subsequently was inserted through a midline incision, and all cats were placed on intermittent positive-pressure ventilation (small animal respirator; Harvard Apparatus, Dover, Mass.). A polyethelyne catheter was inserted through the right femoral artery for measurement of mean arterial blood pressure (MAP) via a strain-guage pressure transducer (Statham P23AC; Gould, Inc., Cleveland, Ohio). Additional polyethelyne catheters were inserted through the right external jugular vein for infusion of anesthesia and through the right femoral vein for infusion of test agent or its vehicle. A midsternal thoracotomy was performed, and the pericardium was opened to allow placement of a 3 -0 silk ligature around the left anterior descending coronary artery (LAD) 8 At the end of the 6-hour experimental period, the ligature around the LAD was retightened, and 25 ml of 0.5% Evans blue was injected into the left atrium and circulated to the area of the myocardium that was perfused by the patent coronary arteries. Thus, the area at risk was determined by negative staining. The heart was excised rapidly and placed in warmed, oxygenated Krebs-Henseleit solution consisting of (mmol/l): NaCI, 118; KCI, 4.75; CaCl2* 2H2O, 2.54; KH2PO4, 1.19; MgSO4 7H20, 1.19; NaHCO3, 12.5; and glucose, 10 .0.
The left circumflex coronary artery (LCx) and LAD were carefully excised for subsequent study of coronary artery ring vasoactivity. The right ventricle and the great vessels were removed, and the left ventricle was sliced parallel to the atrioventricular groove in 3-mmthick sections. The unstained portion of the left ventricle (i.e., total area at risk) was separated from the Evans blue-stained portion of the left ventricle (i.e., area not at risk). The area at risk was again sectioned into 1-mm-thick slices and incubated in 0.1% nitroblue tetrazolium in phosphate buffer (pH 7.4) at 37°C for 15 minutes. The tetrazolium dye forms a blue formazan complex in the presence of coenzymes and dehydrogenases. The irreversibly injured necrotic portion of the myocardium at risk that did not stain was separated from the stained portion of the myocardium (i.e., the ischemic but nonnecrotic area). All three portions of the left ventricular myocardium (i.e., nonischemic, ischemic nonnecrotic, and ischemic necrotic) were weighed; the results were expressed as the area at risk indexed as a percentage of the total left ventricular mass, the area of necrotic tissue was computed as a percentage of the area at risk, and the area of necrotic tissue was computed as a percentage of the total left ventricular mass. The three portions of cat myocardium were stored at -70°C for later assay of myeloperoxidase activity. In three additional cats receiving a saline vehicle instead of L-or D-arginine, the above procedures were repeated except that half of the area at risk was incubated with 3 mM L-arginine to rule out the possibility that L-arginine altered the staining properties of the nitroblue tetrazolium. The area of necrotic tissue computed as a percentage of the area at risk was 46.4±7.2% in the control area at risk samples and 44.5±4.7% in the area at risk samples incubated with L-arginine, indicating that L-arginine had no effect on nitroblue tetrazoliumstaining properties.
Determination of Tissue Myeloperoxidase
Myocardial activity of myeloperoxidase, an enzyme occurring virtually exclusively in neutrophils, was determined using the method of Bradley et al'9 as modified by Mullane et al. 20 The myocardium was homogenized in 0.5% hexadecyltrimethyl ammonium bromide (Sigma Chemical) and dissolved in 50 mM potassium phosphate buffer (pH 6) using a Polytron homogenizer (PCU-2).
Homogenates were centrifuged at 12,500g at 2°C for 30 minutes. The supernatants then were collected and reacted with 0.167 mg/ml O-dianisidine dihydrochloride (Sigma Chemical) and 0.0005% H202 in 50 mmol phosphate buffer (pH 6.0). The 23 During this PMN isolation-and-labeling period, hearts from each cat were removed and placed in warm, oxygenated Krebs-Henseleit buffer. Both the LAD and LCx were removed and cut into 2-to 3-mm segments. The arteries were opened and placed into a cell culture dish filled with 3 ml of Krebs-Henseleit buffer. Isolated labeled PMNs (400,000 PMNs/ml) were incubated for 30 minutes with 3 mM D-or L-arginine. After this 30-minute period, the PMNs were washed with PBS and subsequently added to the cell culture dish containing normal coronary arteries. The PMNs were immediately activated with leukotriene (LT)B4 (100 nM), and coronary segments were removed 20 minutes later to examine PMN adherence to coronary artery endothelium using fluorescence microscopy. The number of PMNs per square millimeter of coronary endothelium were counted in duplicate for each experiment. Isolated Coronary Ring Studies Both LAD and LCx segments were removed and placed into warmed Krebs-Henseleit solution. Isolated coronary vessels were cleaned and cut into rings 2-3 mm long. The rings then were mounted onto stainlesssteel hooks, suspended in 10-ml tissue baths, and subsequently connected to FT-03 force displacement transducers (Grass) to record changes in force on a Grass model 7 oscillographic recorder. The baths were filled with 10 ml of Krebs-Henseleit solution and aerated at 37C with a gas mixture of 95% 02-5% C02. Coronary rings initially were stretched to give a preload of 0.5 g of force and equilibrated for 60 minutes. During this period, the Krebs-Henseleit solution in the tissue baths was replaced every 20 minutes. After equilibration, the rings were exposed to 100 nM U46619 (BIOMOL Research Laboratories Inc., Plymouth Meeting, Pa.), a thromboxane A2 mimetic, to generate about 0.5 g of developed force. Once a stable contraction was obtained, acetylcholine was given to yield a concentration of 0.1, 1, 10, and 100 nM in the bath. After the response stabilized, the rings were washed and allowed to equilibrate to baseline again. The procedure was repeated with the calcium ionophore A-23187 (Calbiochem, La Jolla, Calif.) in amounts that yielded 1, 10, 100, and 1,000 nM and then with NaNO2 (Sigma Chemical) in amounts that yielded 0.1, 1, 10, and 100 uM. NaNO2 was prepared by dissolving the compound in 0.1N HCl and titrating it to pH 2.0.
In six additional cats, the LAD and LCx were removed and placed into warmed Krebs-Henseleit solution after 90 minutes of ischemia and 20 minutes of reperfusion to examine whether in vitro administration of L-arginine could reverse endothelial dysfunction associated with reperfusion. The coronary rings were stabilized and equilibrated as described previously. Endothelium-dependent relaxation was tested with acetylcholine and A23187, and endothelium-independent relaxation was tested with NaNO2. After these responses were determined, the coronary rings were incubated with 3 mmol L-arginine or D-arginine for 30 minutes. The coronary rings then were washed three times with Krebs-Henseleit solution, and vasorelaxation to acetylcholine, A23187, and NaNO2 was repeated. In addition, eight LAD and LCx rings were denuded by gently rubbing a thin cotton tip back and forth to mechanically remove the endothelium. The denuded rings were studied in the same manner as coronary rings, with an intact endothelium subjected to 90 minutes of ischemia and 20 minutes of reperfusion.
Vascular Effects of L-Arginine
The vascular effects of L-arginine were examined in six additional cats. In the first set, the ischemic LAD and nonischemic LCx were isolated, removed, and cut into 2-3-mm rings. The coronary rings were suspended in 10-ml tissue baths and stretched to give a preload of 0.5 g of force as described previously. The arteries were equilibrated for 60 minutes; 3 mmol of L-or D-arginine was then added to the baths, and the effect of L-or At the end of this 30-minute period, the heart was perfused with Krebs-Henseleit buffer without L-arginine for 10 minutes. The ability of the coronary vasculature to vasodilate was tested using the endothelium-independent vasodilator nitroglycerin (50 tg/ml of flow).
Statistical Analysis
All values are presented as mean +SEM of n independent experiments. All data were subjected to ANOVA testing followed by the Bonferroni correction for post hoc t test analysis. Values of p<0.05 were considered statistically significant.
Results

Cardiac Electrophysiological and Hemodynamic Changes
In five cats subjected to sham myocardial ischemia, we observed that intravenous administration of L-arginine administered as a bolus of 30 mg/kg immediately followed by a continuous infusion of 10 mg/kg * min' for 1 hour had no detectable effect on any of the measured hemodynamic or ECG variables. Furthermore, there were no significant differences in any of the variables observed initially between the two myocardial ischemia groups of cats. However, in all cats subjected to coronary artery occlusion, within 10 minutes of LAD occlusion, the ST segment became elevated and peaked at 40 minutes after coronary occlusion. After reperfusion, the ST segment declined to nearly control values. There was no significant difference in peak ST segment elevation between the two myocardial ischemia groups, indicating that the ischemic insult was similar in these cats (Figure 1 ). At reperfusion, there was a noticeable increase in the incidence of premature ventricular contractions (PVCs). Two cats in each myocardial ischemia group developed ventricular fibrillation that was successfully cardioverted to a normal sinus rhythm. There was no overall difference between the myocardial ischemia groups in the number of PVCs occurring after reperfusion, indicating that L-arginine or D-arginine did not exert any overt antiarrhythmic effects. Immediately after coronary occlusion, MAP decreased in all cats. There were no significant differences between the two myocardial ischemia groups at any of the hourly MAP or heart rate readings, suggesting that neither L-arginine nor D-arginine exerted any significant effect on systemic hemodynamics (Tables 1 and 2 ).
Effect of L-Arginine on Reperfusion Myocardial Injury
In every cat subjected to myocardial ischemia, we measured the area at risk of the ischemic heart and the amount of necrotic cardiac tissue expressed as a percentage of both the area at risk and the total left ventricular mass. There was no significant difference between ischemic groups in the area at risk expressed as a percentage of total left ventricular mass, indicating Figure 2 ).
Prevention of PMNAccumulation in Ischemic
Myocardial Tissue by L-Arginine Infiltration of the ischemic region by neutrophils during reperfusion is considered one of the major mechanisms responsible for reperfusion injury. We measured myeloperoxidase activity in the three different portions of the myocardium as a marker for neutrophil accumulation in ischemic tissue. It is evident that in the nonischemic myocardium (i.e., area not at risk), myeloperoxidase activity was very low in both myocardial ischemia groups and there was no significant difference between them, indicating that few neutrophils accumulated in the nonischemic myocardium. However, myocardial ischemia cats receiving D-arginine exhibited a marked increase in myeloperoxidase activity in the necrotic myocardium. In contrast, L-arginine-treated ischemic cats exhibited a significantly lower myeloperoxidase activity in necrotic myocardial tissue (Figure 3 ). Area not at Risk These results indicate that adherence and infiltration of neutrophils to necrotic myocardium were inhibited markedly by L-arginine.
Myeloperoxidase Activity of PMNs
To quantify the amount of neutrophil activity present in cat PMNs, neutrophils isolated from peripheral whole cat blood were counted, digested, and assayed for myeloperoxidase activity. A concentration curve for myeloperoxidase activity is shown in Figure 4 . With an increasing number of neutrophils, there was a linear increase in myeloperoxidase activity. The regression line had a significant r coefficient of 0.965 (p<0.001). The amount of myeloperoxidase activity found in the necrotic myocardium of cats subjected to D-arginine was equal to approximately 1.6x 106 PMNs/100 mg tissue in the necrotic zone. In contrast, the myeloperoxidase activity found in the necrotic myocardium of cats treated with L-arginine was equal to approximately 4.0x iO0 PMNs/100 mg tissue. PMNAdherence to Coronary Artery Endothelium Figure 5 summarizes the effects of L-arginine on PMN adherence. As shown in Figure 5 Representative recordings of rings isolated from cat left anterior descending coronary arteries subjected in vivo to 90 minutes of ischemia and 20 minutes ofreperfusion. The rings were precontracted with the thromboxane A2 mimetic U46619, and responses to the endothelium-dependent vasodilator acetylcholine (ACh) at 100 nM and the endotheliumindependent vasodilator NaNO2 (100 uM) were obtained before (pre-) and after (post-) incubation with 3 mmol L-or D-arginine. The arrows indicate addition of U46619. Dots indicate addition ofACh and NaNO2. endothelium-independent vasodilator NaNO2, however, exhibited full relaxation in all rings. After 30 minutes of incubation with L-arginine, ischemic-reperfused coronary rings exerted significant increases in vasorelaxation in response to acetylcholine and A-23187. This increased vasorelaxant response to acetylcholine did not occur in ischemic-reperfused coronary rings incubated with D-arginine or endothelial-denuded coronary rings incubated with L-arginine. All rings completely relaxed in response to NaNO2 after incubation with either L-or D-arginine. In LCx, maximal relaxation was obtained in all groups before and after admninistration of L-arginine.
Vascular Effects of L-Arginine
The vascular effects of L-arginine also were examined in ischemic LAD and nonischemic LCx rings as well as in isolated, perfused hearts. In isolated coronary artery rings, L-arginine did not significantly alter the basal tone of ischemic LAD rings (Aforce [g]=0.08±0.04 after 60 minutes) or nonischemic LCx rings (Aforce [g]= 0.04±0.02 after 60 minutes) over a 60-minute incubation period. Similarly, L-arginine administered for 30 minutes in isolated, perfused hearts had no significant effect on coronary vascular resistance. These results are summarized in Table 4 .
Discussion
The data obtained in this study clearly demonstrate significant cardioprotective effects of exogenous L-arginine infusion in a feline model of myocardial ischemia/ reperfusion. The myocardial ischemia-plus-D-arginine and myocardial ischemia-plus-L-arginine groups exhibited similar degrees of ischemic insult as indicated by comparable increases both in ST segment elevation and in areas at risk of the left ventricle. Despite these similar degrees of ischemia, L-arginine decreased the necrotic area by approximately 50% of that developing in the D-arginine groups. Although the degree of necrosis appears to be large in the D-arginine control groups, D-arginine did not significantly increase the percentage of necrosis compared with recent studies using saline vehicle controls (40.9+5.1 for D-arginine versus 33.6+4.1 and 37.7+4.5 for saline vehicles, respectively).1825 Earlier findings regarding myocardial ischemia in cats from our laboratory22 and others26'27 indicate that there is very little collateral blood flow in the ischemic cat myocardium. In this regard, cat myocardial blood flow declines 92-93% after LAD occlusion. Because cat coronary collateral blood flow is minor and L-arginine does not significantly alter coronary basal tone, it is unlikely that L-arginine administered for only the last 10 minutes of the 90-minute ischemic period would have increased coronary collateral blood flow to an extent that would significantly decrease myocardial necrosis. Therefore, the myocardial salvage afforded by L-arginine probably was not the result of any direct vasoactive effects of L-arginine. Although it is unlikely, we cannot definitively rule out the possibility that higher native collateral perfusion existed in ischemic cats given Another possible mechanism whereby L-arginine could produce cardioprotective effects in myocardial ischemia/reperfusion would be through coronary vasodilation. This does not appear to be the case, however, because L-arginine administration did not decrease MAP in the sham myocardial ischemia-plus-L-arginine group. Furthermore, 3 mM L-arginine did not alter the basal tone of ischemic or nonischemic coronary arteries or coronary vascular resistance in isolated, perfused hearts. These results confirm the findings of Cooke et al, '4 who found that 3 mM L-arginine did not relax normal rabbit aortic rings and provided further evidence that the cardioprotective effects of L-arginine were not due to coronary vasodilation.
Although L-arginine clearly has cardioprotective effects, systemic administration of L-arginine also exerts several biological effects other than the generation of NO.35 These effects include the increased release of insulin and glucagon from pancreatic cells36 as well as the secretion of growth hormone and prolactin from the pituitary.37 Because L-arginine enhances insulin as well as glucagon secretion, this should offset the effect of insulin on blood glucose levels. Girerd et al '3 also demonstrated that at a concentration equal to that used in our study (i.e., 10 mg/kg -min-1), D-arginine as well as L-arginine induced comparable increases in insulin Weyrich et al L-Arginine in Myocardial Ischemia 287 levels in rabbits, thus suggesting that the insulin-releasing effect of L-arginine is irrelevant to its cardioprotective action. In this connection, we found that D-arginine failed to attenuate endothelial dysfunction, neutrophil accumulation in the ischemic tissue, or myocardial necrosis.
In addition, L-arginine increases the secretions of growth hormone and prolactin from the pituitary. However, the effects of these hormones would most likely be long term (i.e., longer than the 6-hour observation period used in this study), and even if these effects occurred, they would have little or no cardioprotective effect. Although we cannot definitively eliminate the systemic effects of L-arginine on the endocrine system, our in vitro findings of a direct endothelial protective effect of L-arginine but not of D-argrnine suggest that at least one component of the cardioprotective effect of L-arginine in vivo is preservation of NO release by endothelial cells. This endothelial-protective effect of L-arginine appears to occur early during reperfusion (i.e., when 65-75% of endothelial dysfunction occurs27) because L-arginine can reverse endothelial dysfunction after 20 minutes of reperfusion. The ability of L-arginine to reverse endothelial dysfunction after reperfusion coincides with the results of others who have found that L-arginine restores endothelial function in hypercholesterolemic humans38 and rabbits.13 '14 In conclusion, we have demonstrated significant cardioprotective effects after the administration of exogenous L-arginine in a 6-hour model of myocardial ischemia/reperfusion in cats. The necrotic area was reduced by 50% compared with D-arginine-treated cats. Neutrophil accumulation was significantly decreased in the ischemic tissue, and coronary rings isolated from these cats treated with L-arginine exhibited preserved endothelial function as evidenced by a significant increase in their ability to respond to the endothelium-dependent vasodilators ACh and A-23187. Although our data do not allow us to unequivocally state the exact protective mechanism of L-arginine, it appears that L-arginine preserves coronary vascular endothelial release of NO, a finding that previously has been shown to be cardioprotective in this model of ischemia/reperfusion. Further studies are necessary to determine the exact mechanism by which L-arginine preserves endothelial function and attenuates myocardial necrosis.
